Clinical aspects of c-type natriuretic peptide on the cardiovascular system.

CANTÚ SM; DONOSO AS; KOUYOUMDZIAN NM; RUKAVINA MIKUSIC NL; PUYÓ AM; CHOI MR

International Journal of Clinical Endocrinology and Metabolism

Peertechz

Año: 2015 vol. 1 p. 31 - 36

1685-1250

C-type natriuretic peptide (CNP) is one of the threemost important members of the human natriuretic peptide family, sharing withthem a highly conserved 17-aminoacid ring structure, essential to elicit itsbiological actions by binding to its specific receptor NPR-B. CNP acts in aparacrine or autocrine way andit is cleared from plasma circulation by the NPR-C receptor. This is one of the reasons why its plasma levels are usually low. CNP is widely spread in human tissues,being localized in a variety of cells such as cardiac and vascular smoothmuscle cells, chondrocytes, macrophages, glial cells, and renal, brain andreproductive tissues. In the cardiovascular system, CNP is stored inendothelial cells and exert different actions like vasodilation in largeconduction vessels, and anti-proliferative, pro-apoptotic, anti-fibrotic andanti-hypertrophic properties in cardiomyocytes; it also inhibits neointimalrestenosis and reduces cardiac ischemia-reperfusion injury and vascularconstrictive remodeling. In addition, it has been suggested that CNP acts as anendothelium derived hyperpolarizing factor as a consequence of itshyperpolarizing action in resistance arterial smooth vessels muscle. Regardingits clinical aspects, it has been demonstrated the relation between CNP anddifferent cardiovascular pathologies such as heart failure, myocardialinfarction, cardiac remodeling, arterial hypertension, angiogenesis andrevascularization, restenosis, atherosclerosis, pulmonary hypertension, and myocardialaging.